A study of CDK4/6 inhibitor drugs for medulloblastoma, a brain tumor in children
Original title: Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study looks for gene changes that show which medulloblastoma tumors these drugs might work on.
Who this trial is for. This study is about medulloblastoma. It is a rare brain tumor in children, and it comes in 4 types based on the tumor's genes. The team is looking at drugs called CDK4/6 inhibitors. These are palbociclib, ribociclib, and abemaciclib. They are already approved for breast cancer.
Where it stands. The trial has not reported results. The team wants to find gene markers that show which tumors may respond to these drugs. They are also looking at why some tumors stop responding. The source says it is not clear yet whether these drugs help in this brain tumor. That answer is not in yet.
What this means, and what it doesn't
What it could mean: Standard care for this tumor is surgery, radiation, and chemo. Those can be hard on the brain, and children often need care for a long time. Work like this tries to match a drug to a child's own tumor. A family who thinks this fits might ask their care team about it.
What it doesn't mean: This does not mean these drugs are a proven treatment for this tumor. A trial is a test. It is a way to find out if something works, not care your own doctor can give you. Joining a trial is not a promise that it will help. It is not a cure.
Source: ClinicalTrials.gov, September 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.